Additionally, the open-label, phase 2a, plasmaMATCH trial showed that FUL alone was ineffective in patients with advanced breast cancer and ESR1 mutations [32], in agreement with our finding of low activities of FUL in ESR1-mutated models. This evidence concerns the gene ESR1 and breast carcinoma.